Cart is empty 
Description
Buy Ozempic-Orsema (Semaglutide Injection) 0.25 & 0.50 mg
Presentation Buy Ozempic-Orsema (Semaglutide Injection) 0.25 & 0.50 mg
Orsema™ 0.25 mg Injection: Each pre-filled syringe contains 0.25 mg of Semaglutide INN in 0.188 ml solution for injection.
Orsema™ 0.50 mg Injection: Each pre-filled syringe contains 0.50 mg of Semaglutide INN in 0.375 ml solution for injection.
Description
Semaglutide is a GLP-1 analogue with a 94% sequence similarity to human GLP-1. It acts as a GLP-1 receptor agonist, selectively binding to and activating these receptors. Semaglutide reduces blood glucose in a glucose-dependent manner by stimulating insulin secretion and lowering glucagon secretion when blood glucose levels are high. It also delays gastric emptying slightly. During hypoglycemia, Semaglutide decreases insulin secretion without impairing glucagon secretion. Additionally, it helps reduce body weight and fat mass by curbing appetite.
Indications
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- To lower the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
Dosage & Administration of Buy Ozempic-Orsema (Semaglutide Injection) 0.25 & 0.50 Mg:
Start with a dose of 0.25 mg Semaglutide once weekly. After 4 weeks, increase the dose of semaglutide to 0.5 mg once weekly. To further improve glycemic control, the dose can be increased to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose. Administer Semaglutide once weekly, at any time of day, with or without meals. Inject subcutaneously into the thigh, or upper arm. The injection site can be rotated without adjusting the dose. Do not administer Semaglutide intravenously or intramuscularly. If necessary, the day of weekly administration can be changed as long as there are at least 3 days (72 hours) between doses. Continue once-weekly dosing on the new chosen day.
Precautions
- Diabetic Ketoacidosis: Do not use Semaglutide in type 1 diabetes mellitus or to treat diabetic ketoacidosis.
- Pancreatitis: Discontinue Semaglutide if pancreatitis is suspected and do not restart if pancreatitis is confirmed.
- Diabetic Retinopathy: Monitor patients with diabetic retinopathy closely.
Use in Pregnancy & Lactation
Do not use Semaglutide during pregnancy. Stop using Semaglutide (fitaro) at least 2 months before a planned pregnancy. As the risk to a breastfed child cannot be excluded, avoid using Semaglutide while breastfeeding.
Drug Interaction
Semaglutide delays gastric emptying, which can affect the absorption rate of orally administered medications. Use with caution in patients taking oral medications that require rapid gastrointestinal absorption.
Overdose
Overdoses of up to 4 mg in a single dose and up to 4 mg in a week have been reported in clinical trials, with nausea being the most common adverse reaction. There is no specific antidote for Semaglutide overdose. Provide appropriate supportive treatment based on the patient’s clinical signs and symptoms.
Storage
Store at 2°C to 8°C (in a refrigerator). Do not freeze. Keep out of reach of children.
Commercial Pack
Orsema™ 0.25 mg Injection: Each box contains 1 pre-filled syringe of Semaglutide 0.25 mg Injection.
Orsema™ 0.50 mg Injection: Each box contains 1 pre-filled syringe of Semaglutide 0.50 mg Injection.
